SCHEMBL5046628

SCHEMBL5046628

CCCCSc1nc(N)nc(-c2ccco2)c1C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 9/20 0.55
ADORA2A P29274 5/20 0.55
ADORA2B P29275 2/20 0.55
ALDH1A1 P00352 8/20 0.54
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
HPGD P15428 6/20 0.54
MAPT P10636 5/20 0.54
POLB P06746 2/20 0.54
KDM4E B2RXH2 7/20 0.53
LMNA P02545 1/20 0.53
NPSR1 Q6W5P4 3/20 0.47
HTT P42858 2/20 0.47
GAA P10253 1/20 0.47
STAT6 P42226 1/20 0.47
HIF1A Q16665 1/20 0.47
ADORA3 P0DMS8 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 3/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036369 0.88 ALDH1A1 (0.67) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL5046570 0.86 ADORA1 (0.58) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL5046619 0.84 ADORA2A (0.61) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL7152501 0.82 ADORA2A (0.43) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL6441106 0.82 ADORA2A (0.64) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL6440806 0.81 ADORA1 (0.58) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL6441743 0.81 ADORA1 (0.56) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL5041333 0.81 MEN1 (0.69) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL5046699 0.80 ADORA1 (0.57) ADORA1ADORA2AADORA2BALDH1A1MEN1
SCHEMBL6443531 0.77 ADORA2A (0.55) ADORA1ADORA2AADORA2BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4064671-B2 2008-03-19 JP claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP claimed
JP-2003523380-A 2003-08-05 JP claimed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US claimed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP claimed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US claimed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.